Sanofi Unit Touts Long-Term Drug Data
Blueprint Medicines, a Sanofi company, announced four-year data from its PIONEER study of the drug AYVAKIT. The results show a sustained benefit and long-term safety for patients with indolent systemic mastocytosis, a rare blood disorder.
The U.S. Food and Drug Administration (FDA) approved Ayvakit (avapritinib) for adults with indolent systemic mastocytosis on May 22, 2023. This approval marked a significant shift in treatment, making Ayvakit the first and only medicine approved in the U.S. to treat this rare blood disorder by targeting its primary underlying cause. The approval was based on the PIONEER study, a randomized, double-blind, placebo-controlled Phase 2 trial. The study's primary endpoint was the mean change in the total symptom score (TSS) at 24 weeks, which showed a statistically significant improvement for patients taking Ayvakit compared to placebo. Indolent systemic mastocytosis, which accounts for the vast majority of systemic mastocytosis cases, is a rare disease with prevalence estimates in Europe ranging from 1 in 7,700 to 1 in 10,400 people. The disease is characterized by the abnormal accumulation of mast cells, leading to a range of debilitating symptoms across multiple organ systems. Ayvakit works as a potent and selective kinase inhibitor that targets KIT D816V, the mutation that drives approximately 95% of cases of indolent systemic mastocytosis. By inhibiting this specific mutation, the drug blocks the uncontrolled proliferation and activation of mast cells. Prior to Ayvakit's approval for indolent systemic mastocytosis, treatment primarily consisted of supportive care to manage symptoms. The approval for this indication followed an earlier FDA approval in June 2021 for the treatment of advanced systemic mastocytosis. In a major industry move, Sanofi announced its acquisition of Blueprint Medicines. The deal, valued at approximately $9.1 billion, gives Sanofi control of Ayvakit and strengthens its portfolio in rare immunological diseases.
